These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9013384)

  • 1. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
    Schoepp DD; Salhoff CR; Fuson KS; Sacaan AI; Tizzano JP; Ornstein PL; May PC
    J Neural Transm (Vienna); 1996; 103(8-9):905-16. PubMed ID: 9013384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.
    Schoepp DD; Lodge D; Bleakman D; Leander JD; Tizzano JP; Wright RA; Palmer AJ; Salhoff CR; Ornstein PL
    Neuropharmacology; 1995 Sep; 34(9):1159-68. PubMed ID: 8532186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
    Alt A; Weiss B; Ogden AM; Li X; Gleason SD; Calligaro DO; Bleakman D; Witkin JM
    Psychopharmacology (Berl); 2006 Apr; 185(2):240-7. PubMed ID: 16470401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
    Bleakman R; Schoepp DD; Ballyk B; Bufton H; Sharpe EF; Thomas K; Ornstein PL; Kamboj RK
    Mol Pharmacol; 1996 Apr; 49(4):581-5. PubMed ID: 8609884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
    Liljequist S; Cebers G; Kalda A
    Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.
    Ornstein PL; Arnold MB; Allen NK; Bleisch T; Borromeo PS; Lugar CW; Leander JD; Lodge D; Schoepp DD
    J Med Chem; 1996 May; 39(11):2219-31. PubMed ID: 8667365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
    Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kainate receptor-mediated activation of the AP-1 transcription factor complex in cultured rat cerebellar granule cells.
    Kovács AD; Cebers G; Liljequist S
    Brain Res Bull; 2000 May; 52(2):127-33. PubMed ID: 10808083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
    Figueiredo TH; Qashu F; Apland JP; Aroniadou-Anderjaska V; Souza AP; Braga MF
    J Pharmacol Exp Ther; 2011 Feb; 336(2):303-12. PubMed ID: 20962029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Green CE; Swezey R; Yang C; Qashu F; Braga MF
    J Pharmacol Exp Ther; 2013 Jan; 344(1):133-40. PubMed ID: 23042954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia.
    Hicks CA; Ward MA; Swettenham JB; O'Neill MJ
    Eur J Pharmacol; 1999 Sep; 381(2-3):113-9. PubMed ID: 10554878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons.
    Benvenga MJ; Ornstein PL; Leander JD
    J Pharmacol Exp Ther; 1995 Oct; 275(1):164-70. PubMed ID: 7562545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse.
    Rogawski MA; Kurzman PS; Yamaguchi SI; Li H
    Neuropharmacology; 2001; 40(1):28-35. PubMed ID: 11077068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus.
    Bond A; Lodge D; Hicks CA; Ward MA; O'Neill MJ
    Eur J Pharmacol; 1999 Sep; 380(2-3):91-9. PubMed ID: 10513567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.
    O'Neill MJ; Bond A; Ornstein PL; Ward MA; Hicks CA; Hoo K; Bleakman D; Lodge D
    Neuropharmacology; 1998; 37(10-11):1211-22. PubMed ID: 9849659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury?
    Prehn JH; Lippert K; Krieglstein J
    Eur J Pharmacol; 1995 Jan; 292(2):179-89. PubMed ID: 7720791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kainate receptors are involved in synaptic plasticity.
    Bortolotto ZA; Clarke VR; Delany CM; Parry MC; Smolders I; Vignes M; Ho KH; Miu P; Brinton BT; Fantaske R; Ogden A; Gates M; Ornstein PL; Lodge D; Bleakman D; Collingridge GL
    Nature; 1999 Nov; 402(6759):297-301. PubMed ID: 10580501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (S)-5-fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors.
    Larm JA; Cheung NS; Beart PM
    Eur J Pharmacol; 1996 Oct; 314(1-2):249-54. PubMed ID: 8957243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overactivation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate and N-methyl-D-aspartate but not kainate receptors inhibits phosphatidylcholine synthesis before excitotoxic neuronal death.
    Gasull T; DeGregorio-Rocasolano N; Trullas R
    J Neurochem; 2001 Apr; 77(1):13-22. PubMed ID: 11279257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.